Global PARP Inhibitor Market Insights by Region and Application
The global PARP inhibitor market is witnessing unprecedented growth, estimated at USD 6.8 billion in 2025 and projected to reach USD 15.7 billion by 2035 , representing a compound annual growth rate (CAGR) of 8.7% . This surge is fueled by rising awareness of targeted cancer therapies, expansion into rare cancer indications, and integration of precision medicine strategies like biomarker-driven patient selection. Market Drivers The PARP inhibitor market growth is propelled by multiple converging factors: Targeted Therapy Adoption: These inhibitors exploit DNA repair weaknesses in BRCA-mutated and homologous recombination deficiency (HRD) tumors, enhancing treatment efficacy. Precision Medicine: Biomarker-driven patient stratification ensures therapies are directed at patients most likely to benefit, broadening the addressable population. Combination Therapies: Integration with immunotherapy and chemotherapy is expanding indi...